Literature DB >> 21329491

Dengue protease activity: the structural integrity and interaction of NS2B with NS3 protease and its potential as a drug target.

Wai Y Phong1, Nicole J Moreland2, Siew P Lim1, Daying Wen1, Prasad N Paradkar2, Subhash G Vasudevan2.   

Abstract

Flaviviral NS3 serine proteases require the NS2B cofactor region (cNS2B) to be active. Recent crystal structures of WNV (West Nile virus) protease in complex with inhibitors revealed that cNS2B participates in the formation of the protease active site. No crystal structures of ternary complexes are currently available for DENV (dengue virus) to validate the role of cNS2B in active site formation. In the present study, a GST (glutathione transferase) fusion protein of DENV-2 cNS2B49-95 was used as a bait to pull down DENV-2 protease domain (NS3pro). The affinity of NS3pro for cNS2B was strong (equilibrium-binding constant <200 nM) and the heterodimeric complex displayed a catalytic efficiency similar to that of single-chain DENV-2 cNS2B/NS3pro. Various truncations and mutations in the cNS2B sequence showed that conformational integrity of the entire 47 amino acids is critical for protease activity. Furthermore, DENV-2 NS3 protease can be pulled down and transactivated by cNS2B cofactors from DENV-1, -3, -4 and WNV, suggesting that mechanisms for activation are conserved across the flavivirus genus. To validate NS2B as a potential target in allosteric inhibitor development, a cNS2B-specific human monoclonal antibody (3F10) was utilized. 3F10 disrupted the interaction between cNS2B and NS3 in vitro and reduced DENV viral replication in HEK (human embryonic kidney)-293 cells. This provides proof-of-concept for developing assays to find inhibitors that block the interaction between NS2B and NS3 during viral translation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21329491     DOI: 10.1042/BSR20100142

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  12 in total

1.  Policresulen, a novel NS2B/NS3 protease inhibitor, effectively inhibits the replication of DENV2 virus in BHK-21 cells.

Authors:  Deng-wei Wu; Fei Mao; Yan Ye; Jian Li; Chuan-lian Xu; Xiao-min Luo; Jing Chen; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2015-08-17       Impact factor: 6.150

2.  Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction.

Authors:  Zhong Li; Matthew Brecher; Yong-Qiang Deng; Jing Zhang; Srilatha Sakamuru; Binbin Liu; Ruili Huang; Cheri A Koetzner; Christina A Allen; Susan A Jones; Haiying Chen; Na-Na Zhang; Min Tian; Fengshan Gao; Qishan Lin; Nilesh Banavali; Jia Zhou; Nathan Boles; Menghang Xia; Laura D Kramer; Cheng-Feng Qin; Hongmin Li
Journal:  Cell Res       Date:  2017-07-07       Impact factor: 25.617

3.  Allosteric inhibition of the NS2B-NS3 protease from dengue virus.

Authors:  Muslum Yildiz; Sumana Ghosh; Jeffrey A Bell; Woody Sherman; Jeanne A Hardy
Journal:  ACS Chem Biol       Date:  2013-10-28       Impact factor: 5.100

Review 4.  The flavivirus protease as a target for drug discovery.

Authors:  Matthew Brecher; Jing Zhang; Hongmin Li
Journal:  Virol Sin       Date:  2013-11-14       Impact factor: 4.327

5.  1H, 13C and 15N resonance assignment of backbone and IVL-methyl side chain of the S135A mutant NS3pro/NS2B protein of Dengue II virus reveals unique secondary structure features in solution.

Authors:  Peter Agback; Dmitry M Lesovoy; Xiao Han; Renhua Sun; Tatyana Sandalova; Tatiana Agback; Adnane Achour; Vladislav Yu Orekhov
Journal:  Biomol NMR Assign       Date:  2022-02-12       Impact factor: 0.731

6.  Development and utility of an in vitro, fluorescence-based assay for the discovery of novel compounds against dengue 2 viral protease.

Authors:  Gianne Eduard L Ulanday; Kenta Okamoto; Kouichi Morita
Journal:  Trop Med Health       Date:  2016-08-10

7.  An In-Silico Investigation of Phytochemicals as Antiviral Agents Against Dengue Fever.

Authors:  Chelsea N Powers; William N Setzer
Journal:  Comb Chem High Throughput Screen       Date:  2016       Impact factor: 1.339

8.  3,5-Bis(arylidene)-4-piperidones as potential dengue protease inhibitors.

Authors:  Hasnah Osman; Nor Hashima Idris; Ezatul Ezleen Kamarulzaman; Habibah A Wahab; Mohd Zaheen Hassan
Journal:  Acta Pharm Sin B       Date:  2017-05-04       Impact factor: 11.413

9.  Validation of a Novel Zebrafish Model of Dengue Virus (DENV-3) Pathology Using the Pentaherbal Medicine Denguenil Vati.

Authors:  Acharya Balkrishna; Siva Kumar Solleti; Sudeep Verma; Anurag Varshney
Journal:  Biomolecules       Date:  2020-06-28

Review 10.  Antiviral Agents against Flavivirus Protease: Prospect and Future Direction.

Authors:  Subodh K Samrat; Jimin Xu; Zhong Li; Jia Zhou; Hongmin Li
Journal:  Pathogens       Date:  2022-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.